SCHEMBL513589

SCHEMBL513589

CCC(CC)(c1noc(-c2cccc(Cl)c2)n1)P(=O)(O)O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 7/20 0.47
RAB9A P51151 6/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
MAPT P10636 5/20 0.45
TP53 P04637 3/20 0.45
TSHR P16473 4/20 0.44
SMN1; SMN2 Q16637 3/20 0.44
KMT2A Q03164 3/20 0.43
MEN1 O00255 2/20 0.43
MITF O75030 1/20 0.43
PKM P14618 1/20 0.43
GRM5 P41594 1/20 0.43
SMPD1 P17405 1/20 0.42
PLCG2 P16885 1/20 0.41
ADORA2A P29274 1/20 0.41
ADORA1 P30542 1/20 0.41
CNR2 P34972 3/20 0.41
GLA P06280 1/20 0.39
NFKB1 P19838 1/20 0.39
NFKB2 Q00653 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL513092 0.87 NPC1 (0.46) NPC1RAB9AL3MBTL1MAPTTP53
SCHEMBL513254 0.86 TP53 (0.45) NPC1RAB9ATP53SMN1; SMN2GRM5
SCHEMBL513204 0.85 HDAC6 (0.44) NPC1RAB9AL3MBTL1MAPTTP53
SCHEMBL513366 0.84 RAB9A (0.52) NPC1RAB9AMAPTTP53TSHR
SCHEMBL512771 0.84 RAB9A (0.49) NPC1RAB9AL3MBTL1MAPTSMN1; SMN2
SCHEMBL513221 0.80 CHRNB2 (0.49) NPC1RAB9AMAPTTP53TSHR
SCHEMBL513425 0.79 NPC1 (0.45) NPC1RAB9AMAPTTP53TSHR
SCHEMBL512821 0.76 CA2 (0.41) NPC1RAB9AL3MBTL1MAPTKMT2A
SCHEMBL513461 0.76 CCR1 (0.37) NPC1RAB9AMAPTTP53SMN1; SMN2
SCHEMBL512093 0.74 NPC1 (0.41) NPC1RAB9AL3MBTL1MAPTTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120028931-A1 HETEROCYCLIC M-GLU5 ANTAGONISTS RECORDATI IRELAND LIMITED (IE) 2012-02-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120028931-A1 HETEROCYCLIC M-GLU5 ANTAGONISTS OPRM1, GRM5, OPRD1 NPC1 4017/4885RAB9A 2058/4885L3MBTL1 1294/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.